Literature DB >> 9862358

CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection.

B Saha1, S Chattopadhyay, R Germond, D M Harlan, P J Perrin.   

Abstract

Since both the nature and the amplitude of an antigen-specific T cell response are dependent on co-stimulatory signals, we have investigated the role of CD28/CD152-mediated T cell co-stimulation in the regulation of experimental cutaneous leishmaniasis. CD28-deficient mice and their wild-type littermates are equally susceptible to Leishmania major infection. Whole anti-CD152 antibody significantly exacerbates the disease while anti-CD152 Fab ameliorates the disease in genetically susceptible BALB/c mice but not in C57BL/6, a resistant strain. The anti-CD152-induced exacerbation of the disease is accompanied by increased IL-4-secreting cell number, diminished parasite-specific delayed-type hypersensitivity (DTH) response and augmented anti-2,4,6-trinitrophenyl (TNP) IgG1 in response to TNP-leishmanial antigen crude soluble antigen (CSA), suggesting an exaggerated Th2 type of response. Anti-CD152 Fab-mediated amelioration of the disease is associated with increased IFN-gamma-secreting cell number, increased parasite-specific DTH response and enhanced IgG2a isotype in response to TNP-CSA suggesting a Th1 type of response. Unlike TNP-CSA, TNP-keyhole limpet hemocyanin does not induce the change in Ig isotype, indicating that the immunomodulatory effect of anti-CD152 is antigen specific. Anti-CD152 antibody-induced early change in Th subsets suggests an important role for CD152 in determining the course of L. major infection, perhaps by alteration of Th subset differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862358     DOI: 10.1002/(SICI)1521-4141(199812)28:12<4213::AID-IMMU4213>3.0.CO;2-C

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA4 antibody.

Authors:  F P Heinzel; R A Maier
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response.

Authors:  T McGaha; J W Murphy
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

3.  Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity.

Authors:  Dirk Homann; Wolfgang Dummer; Tom Wolfe; Evelyn Rodrigo; Argyrios N Theofilopoulos; Michael B A Oldstone; Matthias G von Herrath
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  LmjF.36.3850, a novel hypothetical Leishmania major protein, contributes to the infection.

Authors:  Shubhranshu Zutshi; Aditya Yashwant Sarode; Soumya Kanti Ghosh; Mukesh Kumar Jha; Raki Sudan; Sunil Kumar; Late Parag Sadhale; Somenath Roy; Bhaskar Saha
Journal:  Immunology       Date:  2021-04-26       Impact factor: 7.215

5.  The Cytotoxic T Lymphocyte Antigen-4 +49A/G Single Nucleotide Polymorphism Association With Visceral Leishmaniasis.

Authors:  Mehrdad Hajilooi; Pegah Lotfi; Farhad Seif; Ahad Bazmani; Mohammad Momeni; Ali Ravary; Mohammad Kazemi Arababadi; Ali Reza Khalilian
Journal:  Jundishapur J Microbiol       Date:  2014-10-01       Impact factor: 0.747

Review 6.  Unraveling the Role of Immune Checkpoints in Leishmaniasis.

Authors:  Rafael de Freitas E Silva; Esther von Stebut
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.